
May 2026 Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cance
This study evaluates the clinical potential of daraxonrasib, a novel oral medication designed to inhibit the RAS mutations that drive growth in over 90% of pancreatic cancers. By targeting the active "on" state of these








